{"id":"https://openalex.org/W1967726440","doi":"https://doi.org/10.1038/sj.bjc.6602428","title":"Epidermal growth factor receptor double targeting by a tyrosine kinase inhibitor (Iressa) and a monoclonal antibody (Cetuximab). Impact on cell growth and molecular factors","display_name":"Epidermal growth factor receptor double targeting by a tyrosine kinase inhibitor (Iressa) and a monoclonal antibody (Cetuximab). Impact on cell growth and molecular factors","publication_year":2005,"publication_date":"2005-03-01","ids":{"openalex":"https://openalex.org/W1967726440","doi":"https://doi.org/10.1038/sj.bjc.6602428","mag":"1967726440","pmid":"https://pubmed.ncbi.nlm.nih.gov/15756277","pmcid":"https://www.ncbi.nlm.nih.gov/pmc/articles/2361947"},"language":"en","primary_location":{"id":"doi:10.1038/sj.bjc.6602428","doi":"https://doi.org/10.1038/sj.bjc.6602428","is_oa":true,"landing_page_url":"https://doi.org/10.1038/sj.bjc.6602428","pdf_url":"https://www.nature.com/articles/6602428.pdf","source":{"id":"https://openalex.org/S62966998","display_name":"British Journal of Cancer","issn_l":"0007-0920","issn":["0007-0920","1532-1827"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-2","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310319965","host_organization_name":"Springer Nature","host_organization_lineage":["https://openalex.org/P4310319965"],"host_organization_lineage_names":["Springer Nature"],"type":"journal"},"license":"cc-by-nc-sa","license_id":"https://openalex.org/licenses/cc-by-nc-sa","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"British Journal of Cancer","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":true,"oa_status":"hybrid","oa_url":"https://www.nature.com/articles/6602428.pdf","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5113773459","display_name":"J-L Fischel","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210151846","display_name":"Centre Antoine Lacassagne","ror":"https://ror.org/05hmfw828","country_code":"FR","type":"facility","lineage":["https://openalex.org/I4210151846"]}],"countries":["FR"],"is_corresponding":false,"raw_author_name":"J-L Fischel","raw_affiliation_strings":["Oncopharmacology Unit Centre Antoine Lacassagne 33, Avenue de Valombrose 06189 Nice Cedex 2, France","Oncopharmacology Unit Centre Antoine Lacassagne 33, France"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Oncopharmacology Unit Centre Antoine Lacassagne 33, Avenue de Valombrose 06189 Nice Cedex 2, France","institution_ids":["https://openalex.org/I4210151846"]},{"raw_affiliation_string":"Oncopharmacology Unit Centre Antoine Lacassagne 33, France","institution_ids":["https://openalex.org/I4210151846"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5055514871","display_name":"Patricia Formento","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210151846","display_name":"Centre Antoine Lacassagne","ror":"https://ror.org/05hmfw828","country_code":"FR","type":"facility","lineage":["https://openalex.org/I4210151846"]}],"countries":["FR"],"is_corresponding":false,"raw_author_name":"P Formento","raw_affiliation_strings":["Oncopharmacology Unit Centre Antoine Lacassagne 33, Avenue de Valombrose 06189 Nice Cedex 2, France","Oncopharmacology Unit Centre Antoine Lacassagne 33, France"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Oncopharmacology Unit Centre Antoine Lacassagne 33, Avenue de Valombrose 06189 Nice Cedex 2, France","institution_ids":["https://openalex.org/I4210151846"]},{"raw_affiliation_string":"Oncopharmacology Unit Centre Antoine Lacassagne 33, France","institution_ids":["https://openalex.org/I4210151846"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5090050048","display_name":"Gerard Alain Milano","orcid":"https://orcid.org/0000-0003-2478-0040","observed_orcids":["https://orcid.org/0000-0003-2478-0040"]},"institutions":[{"id":"https://openalex.org/I4210151846","display_name":"Centre Antoine Lacassagne","ror":"https://ror.org/05hmfw828","country_code":"FR","type":"facility","lineage":["https://openalex.org/I4210151846"]}],"countries":["FR"],"is_corresponding":true,"raw_author_name":"G Milano","raw_affiliation_strings":["Oncopharmacology Unit Centre Antoine Lacassagne 33, Avenue de Valombrose 06189 Nice Cedex 2, France","Oncopharmacology Unit Centre Antoine Lacassagne 33, France"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Oncopharmacology Unit Centre Antoine Lacassagne 33, Avenue de Valombrose 06189 Nice Cedex 2, France","institution_ids":["https://openalex.org/I4210151846"]},{"raw_affiliation_string":"Oncopharmacology Unit Centre Antoine Lacassagne 33, France","institution_ids":["https://openalex.org/I4210151846"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":["https://openalex.org/A5090050048"],"corresponding_institution_ids":["https://openalex.org/I4210151846"],"apc_list":{"value":5190,"currency":"USD","value_usd":5190},"apc_paid":{"value":5190,"currency":"USD","value_usd":5190},"fwci":4.4798,"has_fulltext":true,"cited_by_count":51,"citation_normalized_percentile":{"value":0.94834923,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":88,"max":96},"biblio":{"volume":"92","issue":"6","first_page":"1063","last_page":"1068"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10755","display_name":"HER2/EGFR in Cancer Research","score":0.9984999895095825,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10755","display_name":"HER2/EGFR in Cancer Research","score":0.9984999895095825,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10417","display_name":"Lung Cancer Treatments and Mutations","score":0.00139999995008111,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11067","display_name":"Colorectal Cancer Treatments and Studies","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/epidermal-growth-factor-receptor","display_name":"epidermal growth factor receptor","score":0.9980000257492065},{"id":"https://openalex.org/keywords/cetuximab","display_name":"cetuximab","score":0.9580000042915344},{"id":"https://openalex.org/keywords/gefitinib","display_name":"gefitinib","score":0.9240000247955322},{"id":"https://openalex.org/keywords/tyrosine-kinase-inhibitors","display_name":"tyrosine kinase inhibitors","score":0.718999981880188},{"id":"https://openalex.org/keywords/monoclonal-antibodies","display_name":"monoclonal antibodies","score":0.9229999780654907},{"id":"https://openalex.org/keywords/combination-therapy","display_name":"combination therapy","score":0.824999988079071},{"id":"https://openalex.org/keywords/drug-antagonism","display_name":"drug antagonism","score":0.800000011920929},{"id":"https://openalex.org/keywords/egfr-signaling","display_name":"EGFR signaling","score":0.6370000243186951},{"id":"https://openalex.org/keywords/apoptosis","display_name":"apoptosis","score":0.871999979019165},{"id":"https://openalex.org/keywords/poly-adp-ribose-polymerase","display_name":"poly(ADP-ribose) polymerase","score":0.6930000185966492},{"id":"https://openalex.org/keywords/egfr-expression","display_name":"EGFR expression","score":0.5569999814033508}],"concepts":[{"id":"https://openalex.org/C2779998722","wikidata":"https://www.wikidata.org/wiki/Q420296","display_name":"Cetuximab","level":4,"score":0.9678750038146973},{"id":"https://openalex.org/C2779438470","wikidata":"https://www.wikidata.org/wiki/Q424401","display_name":"Epidermal growth factor receptor","level":3,"score":0.7777076363563538},{"id":"https://openalex.org/C542903549","wikidata":"https://www.wikidata.org/wiki/Q422248","display_name":"Monoclonal antibody","level":3,"score":0.6977971792221069},{"id":"https://openalex.org/C42362537","wikidata":"https://www.wikidata.org/wiki/Q87099740","display_name":"Tyrosine kinase","level":3,"score":0.6099811792373657},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.5550711154937744},{"id":"https://openalex.org/C2780580887","wikidata":"https://www.wikidata.org/wiki/Q417824","display_name":"Gefitinib","level":4,"score":0.5380250215530396},{"id":"https://openalex.org/C26375932","wikidata":"https://www.wikidata.org/wiki/Q118226","display_name":"Growth factor receptor","level":3,"score":0.5056717395782471},{"id":"https://openalex.org/C163864487","wikidata":"https://www.wikidata.org/wiki/Q6901461","display_name":"Monoclonal","level":4,"score":0.4499548077583313},{"id":"https://openalex.org/C2778820342","wikidata":"https://www.wikidata.org/wiki/Q906415","display_name":"Tyrosine-kinase inhibitor","level":3,"score":0.4475548565387726},{"id":"https://openalex.org/C2777506169","wikidata":"https://www.wikidata.org/wiki/Q424401","display_name":"EGFR inhibitors","level":4,"score":0.4417840242385864},{"id":"https://openalex.org/C2776362946","wikidata":"https://www.wikidata.org/wiki/Q424374","display_name":"Epidermal growth factor","level":3,"score":0.4290994703769684},{"id":"https://openalex.org/C2781230642","wikidata":"https://www.wikidata.org/wiki/Q492646","display_name":"Targeted therapy","level":3,"score":0.4197573661804199},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.4045315682888031},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.3508608937263489},{"id":"https://openalex.org/C159654299","wikidata":"https://www.wikidata.org/wiki/Q79460","display_name":"Antibody","level":2,"score":0.31231799721717834},{"id":"https://openalex.org/C170493617","wikidata":"https://www.wikidata.org/wiki/Q208467","display_name":"Receptor","level":2,"score":0.3064212501049042},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.2857714295387268},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.2542736530303955},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.20770615339279175}],"mesh":[{"descriptor_ui":"D000068818","descriptor_name":"Cetuximab","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000077156","descriptor_name":"Gefitinib","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000911","descriptor_name":"Antibodies, Monoclonal","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D002470","descriptor_name":"Cell Survival","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D004305","descriptor_name":"Dose-Response Relationship, Drug","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D011799","descriptor_name":"Quinazolines","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D045744","descriptor_name":"Cell Line, Tumor","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D061067","descriptor_name":"Antibodies, Monoclonal, Humanized","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D066246","descriptor_name":"ErbB Receptors","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":true}],"locations_count":4,"locations":[{"id":"doi:10.1038/sj.bjc.6602428","doi":"https://doi.org/10.1038/sj.bjc.6602428","is_oa":true,"landing_page_url":"https://doi.org/10.1038/sj.bjc.6602428","pdf_url":"https://www.nature.com/articles/6602428.pdf","source":{"id":"https://openalex.org/S62966998","display_name":"British Journal of Cancer","issn_l":"0007-0920","issn":["0007-0920","1532-1827"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-2","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310319965","host_organization_name":"Springer Nature","host_organization_lineage":["https://openalex.org/P4310319965"],"host_organization_lineage_names":["Springer Nature"],"type":"journal"},"license":"cc-by-nc-sa","license_id":"https://openalex.org/licenses/cc-by-nc-sa","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"British Journal of Cancer","raw_type":"journal-article"},{"id":"pmh:oai:pubmedcentral.nih.gov:2361947","doi":null,"is_oa":true,"landing_page_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/2361947","pdf_url":null,"source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Br J Cancer","raw_type":"Text"},{"id":"pmid:15756277","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/15756277","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"British journal of cancer","raw_type":"Journal Article"},{"id":"pmh:oai:CiteSeerX.psu:10.1.1.280.7600","doi":null,"is_oa":false,"landing_page_url":"http://citeseerx.ist.psu.edu/viewdoc/summary?doi=10.1.1.280.7600","pdf_url":null,"source":null,"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"ftp://ftp.ncbi.nlm.nih.gov/pub/pmc/d6/8d/Br_J_Cancer_2005_Mar_28_92(6)_1063-1068.tar.gz","raw_type":"text"}],"best_oa_location":{"id":"doi:10.1038/sj.bjc.6602428","doi":"https://doi.org/10.1038/sj.bjc.6602428","is_oa":true,"landing_page_url":"https://doi.org/10.1038/sj.bjc.6602428","pdf_url":"https://www.nature.com/articles/6602428.pdf","source":{"id":"https://openalex.org/S62966998","display_name":"British Journal of Cancer","issn_l":"0007-0920","issn":["0007-0920","1532-1827"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-2","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310319965","host_organization_name":"Springer Nature","host_organization_lineage":["https://openalex.org/P4310319965"],"host_organization_lineage_names":["Springer Nature"],"type":"journal"},"license":"cc-by-nc-sa","license_id":"https://openalex.org/licenses/cc-by-nc-sa","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"British Journal of Cancer","raw_type":"journal-article"},"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":0.9537000060081482}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":true,"pdf":true},"content_urls":{"pdf":"https://content.openalex.org/works/W1967726440.pdf","grobid_xml":"https://content.openalex.org/works/W1967726440.grobid-xml"},"referenced_works_count":30,"referenced_works":["https://openalex.org/W26155307","https://openalex.org/W51995314","https://openalex.org/W605349899","https://openalex.org/W1554880727","https://openalex.org/W1931708823","https://openalex.org/W1967368177","https://openalex.org/W1967759145","https://openalex.org/W1977340600","https://openalex.org/W1983104536","https://openalex.org/W1984375602","https://openalex.org/W2007206696","https://openalex.org/W2007314461","https://openalex.org/W2030047701","https://openalex.org/W2043696829","https://openalex.org/W2053078719","https://openalex.org/W2056816200","https://openalex.org/W2076794242","https://openalex.org/W2077945404","https://openalex.org/W2079244398","https://openalex.org/W2098924026","https://openalex.org/W2128402413","https://openalex.org/W2129432386","https://openalex.org/W2137600224","https://openalex.org/W2143536404","https://openalex.org/W2143604533","https://openalex.org/W2146404049","https://openalex.org/W2168377135","https://openalex.org/W2241063488","https://openalex.org/W2405262285","https://openalex.org/W2417837598"],"related_works":["https://openalex.org/W2064022140","https://openalex.org/W2137600224","https://openalex.org/W2129579482","https://openalex.org/W7095324416","https://openalex.org/W2129432386","https://openalex.org/W7098785378","https://openalex.org/W2024036818","https://openalex.org/W2144315144","https://openalex.org/W2267868684","https://openalex.org/W2059999122"],"abstract_inverted_index":{"Among":[0],"the":[1,5,11,22,26,35,53,66,69,99,105,110,128,160,175],"recent":[2],"advances":[3],"in":[4,104,140,153,163,179],"molecular":[6,138],"targeted":[7],"therapy":[8],"of":[9,34,38,40,55,68,107,121],"cancer,":[10],"applications":[12],"focused":[13],"on":[14,174],"epidermal":[15],"growth":[16],"factor":[17],"receptor":[18],"(EGFR)":[19],"are":[20],"currently":[21],"most":[23,27,100],"promising":[24],"and":[25,43,88,94,123,143,170,187],"advanced":[28,102],"at":[29,76],"clinical":[30],"level.":[31],"In":[32],"view":[33],"different":[36],"modes":[37],"action":[39],"monoclonal":[41,185],"antibodies":[42],"tyrosine":[44],"kinase":[45],"inhibitors":[46],"(TKI),":[47],"it":[48],"is":[49],"tempting":[50,171],"to":[51,72,150],"examine":[52],"effect":[54],"a":[56,151,180,184,188],"combination":[57,75,120,158],"between":[58],"these":[59,115],"two":[60,81,116],"EGFR":[61,144,154,176],"targeting":[62],"approaches.":[63],"It":[64],"was":[65,125],"purpose":[67],"present":[70],"study":[71],"test":[73],"this":[74],"experimental":[77],"level":[78],"by":[79,137],"using":[80,114],"epidermoid":[82],"human":[83],"cell":[84,129],"lines":[85],"CAL":[86,89],"33":[87],"39.":[90],"As":[91],"C225":[92,122],"(Cetuximab)":[93],"ZD1839":[95,124],"(Iressa)":[96],"are,":[97],"respectively,":[98],"clinically":[101],"drugs":[103],"category":[106],"anti-EGFR":[108],"drugs,":[109],"experiments":[111],"were":[112,135],"performed":[113],"representative":[117],"compounds.":[118],"The":[119],"antagonistic":[126,133],"whatever":[127],"line":[130],"considered.":[131],"These":[132,165],"effects":[134],"corroborated":[136],"changes":[139],"apoptosis":[141],"(PARP)":[142],"signalling":[145],"(phospho-p42-44).":[146],"Drugs":[147],"alone":[148],"led":[149],"diminution":[152],"levels,":[155],"while":[156],"their":[157],"increased":[159],"cellular":[161],"expression":[162],"EGFR.":[164],"data":[166],"suggest":[167],"that":[168],"new":[169],"treatment":[172],"strategies":[173],"target":[177],"consisting":[178],"double":[181],"hit":[182],"with":[183,193],"antibody":[186],"TKI":[189],"must":[190],"be":[191],"considered":[192],"caution.":[194]},"counts_by_year":[{"year":2024,"cited_by_count":1},{"year":2023,"cited_by_count":1},{"year":2019,"cited_by_count":1},{"year":2018,"cited_by_count":1},{"year":2016,"cited_by_count":2},{"year":2015,"cited_by_count":2},{"year":2014,"cited_by_count":1},{"year":2013,"cited_by_count":2},{"year":2012,"cited_by_count":2}],"updated_date":"2026-11-07T11:25:07.637180","created_date":"2016-06-24T00:00:00"}